FKHR (Phospho-Ser256) Conjugated Antibody

Catalog No: #C11115



Package Size: #C11115-AF350 100ul #C11115-AF405 100ul #C11115-AF488 100ul #C11115-AF555 100ul #C11115-AF555 100ul #C11115-AF555 100ul #C11115-AF5594 100ul #C11115-AF680 100ul #C11115-AF750 100ul #C11115-Biotin 100ul #C11115-Biotin 100ul #C11115-Comugated 50ul

| Description | |
|-----------------------|--|
| Product Name | FKHR (Phospho-Ser256) Conjugated Antibody |
| Host Species | Rabbit |
| Clonality | Polyclonal |
| Applications | WB,IHC,IF,ELISAB |
| Species Reactivity | Human,Mouse,Rat,Drosophila |
| Specificity | The antibody detects endogenous level of FKHR only when phosphorylated at serine 256. |
| Immunogen Description | Peptide sequence around phosphorylation site of serine 256 (A-A-S(p)-M-D) derived from Human FKHR. |
| Conjugates | Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750 |
| Other Names | FKHR; FOXO1 |
| Accession No. | Swiss-Prot#:Q12778NCBI Gene ID:2308NCBI mRNA#:NM_002015.3 NCBI Protein#:NP_002006.2 |
| Calculated MW | 78-82 |
| Formulation | 0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide |
| Storage | Store at 4°C in dark for 6 months |

Application Details

WB: 1:50-1:200 IF:1:50-1:200

Product Description

Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.

Background

Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress. Binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3'. Activity suppressed by insulin. Main regulator of redox balance and osteoblast numbers and controls bone mass. Orchestrates the endocrine function of the skeleton in regulating glucose metabolism. Acts syngernistically with ATF4 to suppress osteocalcin/BGLAP activity, increasing glucose levels and triggering glucose intolerance and insulin insensitivity. Also suppresses the transcriptional activity of RUNX2, an upstream activator of osteocalcin/BGLAP. In hepatocytes, promotes gluconeogenesis by acting together with PPARGC1A to activate the expression of genes such as IGFBP1, G6PC and PPCK1. Important regulator of cell death acting downstream of CDK1, PKB/AKT1 and SKT4/MST1. Promotes neural cell death. Mediates insulin action on adipose. Regulates the expression of adipogenic genes such as PPARG during preadipocyte differentiation and, adipocyte size and adipose tissue-specific gene expression in response to excessive calorie intake. Regulates the transcriptional activity of GADD45A and repair of nitric oxide-damaged DNA in beta-cells.

| Note: This product is for in vitro research use only and is not intended for use in humans or animals. | | | |
|--|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |